pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

963 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1557Hematology1354Pulmonology1264Vaccines
  • Veradermics reports positive Phase 3 results for oral baldness pill
    Veradermics said its experimental oral formulation of minoxidil met the primary goal of its Phase 3 trial, showing significantly more new hair growth over six months compared with placebo. The dru…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Oruka’s experimental psoriasis drug achieves near-complete skin clearance in Phase 2 trial
    Oruka Therapeutics reported that its experimental IL-23 inhibitor ORKA-001 cleared the skin of 40 of 63 patients (about 63%) in a Phase 2 study, achieving a PASI 100 response at 16 weeks. A further…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
← prev
page 39 of 39
next →
73
fda recalls71
fda medwatch62
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain501
Endocrinology & Metabolism495
Infectious Disease457
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • European regulators recommend Sanofi's MS drug tolebrutinib for approval after US rejection
    European Medicines Agency officials issued a positive recommendation for tolebrutinib, an experimental multiple sclerosis therapy from Sanofi, after the U.S. FDA rejected the drug earlier this year…
    BioPharma Dive · 4mo agoRegulatoryPositive↗ source
  • Lilly shares slide as Foundayo prescriptions lag expectations, while Novo's Wegovy gains momentum
    Eli Lilly's stock fell nearly 5% after the latest weekly prescription count for its obesity drug Foundayo missed analysts' expectations. IQVIA data showed U.S. prescriptions for Foundayo reached 3…
    BioPharma Dive · 4mo agoNegative readoutNegative↗ source
  • FDA approves Regeneron’s Otarmeni gene therapy for rare inherited hearing loss
    The FDA has approved Otarmeni, a gene therapy from Regeneron, marking the first therapy cleared under the agency’s national priority voucher program and will be provided to eligible patients at no…
    BioPharma Dive · 4mo agoApprovalPositive↗ source
  • AbbVie to invest $1.4 billion in new 185-acre manufacturing campus in Durham, North Carolina
    AbbVie announced a $1.4 billion investment to build a large manufacturing campus in Durham, North Carolina. The 185-acre site will focus on producing small-volume parenteral medicines such as vial…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Sanofi beats Q1 sales forecasts, driven by strong Dupixent demand
    Sanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflamma…
    BioPharma Dive · 4mo agoEarningsPositive↗ source
  • Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressure
    Roche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…
    BioPharma Dive · 4mo agoEarningsNeutral↗ source
  • Revolution Medicines' early-stage pancreatic cancer drug shows tumor control in half of patients
    Revolution Medicines reported that its experimental therapy daraxonrasib helped control tumors in at least half of patients with early-stage pancreatic cancer, whether given alone or with chemother…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Moderna launches Phase 3 trial of mRNA bird flu vaccine after US funding cut
    Moderna has begun enrolling participants in a Phase 3 trial of its mRNA-1018 vaccine targeting H5 influenza (bird flu). The trial aims to include about 4,000 healthy adults in the United States and…
    BioPharma Dive · 4mo agoPositive↗ source
  • Merck commits up to $1 billion to Google Cloud partnership to accelerate AI across its operations
    Merck announced a multiyear partnership with Google Cloud, investing up to $1 billion to embed AI tools throughout its research, development, manufacturing, commercial and corporate functions. The…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • Owkin launches autonomous AI scientist to accelerate drug discovery
    A new AI platform from Owkin, called K Pro, is designed to act as an autonomous "AI scientist," handling complex research questions that traditionally require teams of scientists. The system build…
    BioPharma Dive · 4mo agoPositive↗ source